Figure 3.

Longitudinal monitoring of the effectiveness of miltefosine in post-kala-azar dermal leishmaniasis (PKDL). (A) Before-and-after plots indicating parasite load at disease presentation (●; week 0), at the end of 12 weeks of treatment (t/t) with miltefosine (■; week 12) and/or at ≥6 months posttreatment (▲; week > 36); P <0.001 as compared with presentation. (B) Representative clinical profiles of longitudinally monitored patients with polymorphic PKDL (i) or macular PKDL (ii), at disease presentation, at the end of 12 weeks treatment with miltefosine, and at ≥6 months posttreatment.